This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, licensing and asset acquisition deals, and an epidemiological overview.
Author: Pharma Intelligence
Publisher: Datamonitor Healthcare
Published: 06 October 2022
Number of pages:21
This Market Spotlight report covers the Norovirus market, comprising key pipeline drugs, clinical trials, probability of success, and an epidemiological overview.
Worldwide, about one out of every five cases of acute gastroenteritis is caused by norovirus. Norovirus is responsible for approximately 685 million cases of gastroenteritis every year.
Globally, norovirus is estimated to cause approximately 200,000 deaths annually, including an estimated 70,000 child deaths, mainly in developing countries.
The largest proportion of industry-sponsored assets in active clinical development for norovirus are in Phase I. Most of the clinical products currently in development for norovirus are vaccines. The pipeline drugs are administered via the oral, intranasal, and percutaneous catheter/injection routes.
The overall likelihood of approval of a Phase I antiviral asset is 12.1%, and the average probability an asset advances from Phase III is 64.2%. Assets, on average, take 8.5 years from Phase I to approval, compared to 9.1 years in the overall infectious disease space.
The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for norovirus have been in the early and mid-phases of development, with 94% of trials in Phase I–II, and only 6% in Phase III–IV.
The US has a substantial lead in the number of norovirus clinical trials globally.
Takeda has the highest number of completed clinical trials for norovirus, with 12 trials.
Takeda and Vaxart lead the industry sponsors with the highest overall number of clinical trials for norovirus.
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
9 Norovirus outbreaks
9 Challenges for vaccine development
11 PIPELINE DRUGS
15 PROBABILITY OF SUCCESS
16 CLINICAL TRIAL LANDSCAPE
17 Sponsors by status
18 Sponsors by phase
LIST OF FIGURES
11 Figure 1: Overview of pipeline drugs for norovirus in the US
11 Figure 2: Pipeline drugs for norovirus, by company
12 Figure 3: Pipeline drugs for norovirus, by drug type
12 Figure 4: Pipeline drugs for norovirus, by classification
15 Figure 5: Probability of success in the antiviral pipeline
16 Figure 6: Clinical trials in norovirus
16 Figure 7: Top 10 drugs for clinical trials in norovirus
17 Figure 8: Top 10 companies for clinical trials in norovirus
17 Figure 9: Trial locations in norovirus
18 Figure 10: Norovirus trials status
18 Figure 11: Norovirus trials sponsors, by phase
LIST OF TABLES
13 Table 1: Pipeline drugs for norovirus in the US
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.